The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Gene Therapy for CNS Disorders Market Research Report 2025
Synopsis
Gene Therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.
The global Gene Therapy for CNS Disorders market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy for CNS Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy for CNS Disorders.
Report Scope
The Gene Therapy for CNS Disorders market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gene Therapy for CNS Disorders market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Therapy for CNS Disorders companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead (Kite Pharma)
Amgen (BioVex)
Novartis
Roche (Spark Therapeutics)
Bluebird Bio
Segment by Type
Ex Vivo
In Vivo
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gene Therapy for CNS Disorders companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Gene Therapy is an experimental treatment that involves introducing genetic material into a person’s cells to fight or prevent disease. A gene can be delivered to a cell using a carrier known as a “vector.” The most common types of vectors used in gene therapy are viruses. The viruses used in gene therapy are altered to make them safe, although some risks still exist with gene therapy. The technology is still in its infancy.
The global Gene Therapy for CNS Disorders market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Gene Therapy for CNS Disorders, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Therapy for CNS Disorders.
Report Scope
The Gene Therapy for CNS Disorders market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gene Therapy for CNS Disorders market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gene Therapy for CNS Disorders companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead (Kite Pharma)
Amgen (BioVex)
Novartis
Roche (Spark Therapeutics)
Bluebird Bio
Segment by Type
Ex Vivo
In Vivo
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Gene Therapy for CNS Disorders companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Gene Therapy for CNS Disorders Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Ex Vivo
1.2.3 In Vivo
1.3 Market by Application
1.3.1 Global Gene Therapy for CNS Disorders Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Gene Therapy for CNS Disorders Market Perspective (2019-2030)
2.2 Gene Therapy for CNS Disorders Growth Trends by Region
2.2.1 Global Gene Therapy for CNS Disorders Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Gene Therapy for CNS Disorders Historic Market Size by Region (2019-2024)
2.2.3 Gene Therapy for CNS Disorders Forecasted Market Size by Region (2025-2030)
2.3 Gene Therapy for CNS Disorders Market Dynamics
2.3.1 Gene Therapy for CNS Disorders Industry Trends
2.3.2 Gene Therapy for CNS Disorders Market Drivers
2.3.3 Gene Therapy for CNS Disorders Market Challenges
2.3.4 Gene Therapy for CNS Disorders Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Gene Therapy for CNS Disorders Players by Revenue
3.1.1 Global Top Gene Therapy for CNS Disorders Players by Revenue (2019-2024)
3.1.2 Global Gene Therapy for CNS Disorders Revenue Market Share by Players (2019-2024)
3.2 Global Gene Therapy for CNS Disorders Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Gene Therapy for CNS Disorders Revenue
3.4 Global Gene Therapy for CNS Disorders Market Concentration Ratio
3.4.1 Global Gene Therapy for CNS Disorders Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Gene Therapy for CNS Disorders Revenue in 2023
3.5 Gene Therapy for CNS Disorders Key Players Head office and Area Served
3.6 Key Players Gene Therapy for CNS Disorders Product Solution and Service
3.7 Date of Enter into Gene Therapy for CNS Disorders Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Gene Therapy for CNS Disorders Breakdown Data by Type
4.1 Global Gene Therapy for CNS Disorders Historic Market Size by Type (2019-2024)
4.2 Global Gene Therapy for CNS Disorders Forecasted Market Size by Type (2025-2030)
5 Gene Therapy for CNS Disorders Breakdown Data by Application
5.1 Global Gene Therapy for CNS Disorders Historic Market Size by Application (2019-2024)
5.2 Global Gene Therapy for CNS Disorders Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Gene Therapy for CNS Disorders Market Size (2019-2030)
6.2 North America Gene Therapy for CNS Disorders Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Gene Therapy for CNS Disorders Market Size by Country (2019-2024)
6.4 North America Gene Therapy for CNS Disorders Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Gene Therapy for CNS Disorders Market Size (2019-2030)
7.2 Europe Gene Therapy for CNS Disorders Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Gene Therapy for CNS Disorders Market Size by Country (2019-2024)
7.4 Europe Gene Therapy for CNS Disorders Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Gene Therapy for CNS Disorders Market Size (2019-2030)
8.2 Asia-Pacific Gene Therapy for CNS Disorders Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Gene Therapy for CNS Disorders Market Size by Region (2019-2024)
8.4 Asia-Pacific Gene Therapy for CNS Disorders Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Gene Therapy for CNS Disorders Market Size (2019-2030)
9.2 Latin America Gene Therapy for CNS Disorders Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Gene Therapy for CNS Disorders Market Size by Country (2019-2024)
9.4 Latin America Gene Therapy for CNS Disorders Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Gene Therapy for CNS Disorders Market Size (2019-2030)
10.2 Middle East & Africa Gene Therapy for CNS Disorders Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Gene Therapy for CNS Disorders Market Size by Country (2019-2024)
10.4 Middle East & Africa Gene Therapy for CNS Disorders Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gilead (Kite Pharma)
11.1.1 Gilead (Kite Pharma) Company Detail
11.1.2 Gilead (Kite Pharma) Business Overview
11.1.3 Gilead (Kite Pharma) Gene Therapy for CNS Disorders Introduction
11.1.4 Gilead (Kite Pharma) Revenue in Gene Therapy for CNS Disorders Business (2019-2024)
11.1.5 Gilead (Kite Pharma) Recent Development
11.2 Amgen (BioVex)
11.2.1 Amgen (BioVex) Company Detail
11.2.2 Amgen (BioVex) Business Overview
11.2.3 Amgen (BioVex) Gene Therapy for CNS Disorders Introduction
11.2.4 Amgen (BioVex) Revenue in Gene Therapy for CNS Disorders Business (2019-2024)
11.2.5 Amgen (BioVex) Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Gene Therapy for CNS Disorders Introduction
11.3.4 Novartis Revenue in Gene Therapy for CNS Disorders Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Roche (Spark Therapeutics)
11.4.1 Roche (Spark Therapeutics) Company Detail
11.4.2 Roche (Spark Therapeutics) Business Overview
11.4.3 Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Introduction
11.4.4 Roche (Spark Therapeutics) Revenue in Gene Therapy for CNS Disorders Business (2019-2024)
11.4.5 Roche (Spark Therapeutics) Recent Development
11.5 Bluebird Bio
11.5.1 Bluebird Bio Company Detail
11.5.2 Bluebird Bio Business Overview
11.5.3 Bluebird Bio Gene Therapy for CNS Disorders Introduction
11.5.4 Bluebird Bio Revenue in Gene Therapy for CNS Disorders Business (2019-2024)
11.5.5 Bluebird Bio Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Gene Therapy for CNS Disorders Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Ex Vivo
Table 3. Key Players of In Vivo
Table 4. Global Gene Therapy for CNS Disorders Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Gene Therapy for CNS Disorders Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Gene Therapy for CNS Disorders Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Gene Therapy for CNS Disorders Market Share by Region (2019-2024)
Table 8. Global Gene Therapy for CNS Disorders Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Gene Therapy for CNS Disorders Market Share by Region (2025-2030)
Table 10. Gene Therapy for CNS Disorders Market Trends
Table 11. Gene Therapy for CNS Disorders Market Drivers
Table 12. Gene Therapy for CNS Disorders Market Challenges
Table 13. Gene Therapy for CNS Disorders Market Restraints
Table 14. Global Gene Therapy for CNS Disorders Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Gene Therapy for CNS Disorders Market Share by Players (2019-2024)
Table 16. Global Top Gene Therapy for CNS Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for CNS Disorders as of 2023)
Table 17. Ranking of Global Top Gene Therapy for CNS Disorders Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Gene Therapy for CNS Disorders Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Gene Therapy for CNS Disorders Product Solution and Service
Table 21. Date of Enter into Gene Therapy for CNS Disorders Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Gene Therapy for CNS Disorders Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Gene Therapy for CNS Disorders Revenue Market Share by Type (2019-2024)
Table 25. Global Gene Therapy for CNS Disorders Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Gene Therapy for CNS Disorders Revenue Market Share by Type (2025-2030)
Table 27. Global Gene Therapy for CNS Disorders Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Gene Therapy for CNS Disorders Revenue Market Share by Application (2019-2024)
Table 29. Global Gene Therapy for CNS Disorders Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Gene Therapy for CNS Disorders Revenue Market Share by Application (2025-2030)
Table 31. North America Gene Therapy for CNS Disorders Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Gene Therapy for CNS Disorders Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Gene Therapy for CNS Disorders Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Gene Therapy for CNS Disorders Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Gene Therapy for CNS Disorders Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Gene Therapy for CNS Disorders Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Gene Therapy for CNS Disorders Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Gene Therapy for CNS Disorders Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Gene Therapy for CNS Disorders Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Gene Therapy for CNS Disorders Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Gene Therapy for CNS Disorders Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Gene Therapy for CNS Disorders Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Gene Therapy for CNS Disorders Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Gene Therapy for CNS Disorders Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Gene Therapy for CNS Disorders Market Size by Country (2025-2030) & (US$ Million)
Table 46. Gilead (Kite Pharma) Company Detail
Table 47. Gilead (Kite Pharma) Business Overview
Table 48. Gilead (Kite Pharma) Gene Therapy for CNS Disorders Product
Table 49. Gilead (Kite Pharma) Revenue in Gene Therapy for CNS Disorders Business (2019-2024) & (US$ Million)
Table 50. Gilead (Kite Pharma) Recent Development
Table 51. Amgen (BioVex) Company Detail
Table 52. Amgen (BioVex) Business Overview
Table 53. Amgen (BioVex) Gene Therapy for CNS Disorders Product
Table 54. Amgen (BioVex) Revenue in Gene Therapy for CNS Disorders Business (2019-2024) & (US$ Million)
Table 55. Amgen (BioVex) Recent Development
Table 56. Novartis Company Detail
Table 57. Novartis Business Overview
Table 58. Novartis Gene Therapy for CNS Disorders Product
Table 59. Novartis Revenue in Gene Therapy for CNS Disorders Business (2019-2024) & (US$ Million)
Table 60. Novartis Recent Development
Table 61. Roche (Spark Therapeutics) Company Detail
Table 62. Roche (Spark Therapeutics) Business Overview
Table 63. Roche (Spark Therapeutics) Gene Therapy for CNS Disorders Product
Table 64. Roche (Spark Therapeutics) Revenue in Gene Therapy for CNS Disorders Business (2019-2024) & (US$ Million)
Table 65. Roche (Spark Therapeutics) Recent Development
Table 66. Bluebird Bio Company Detail
Table 67. Bluebird Bio Business Overview
Table 68. Bluebird Bio Gene Therapy for CNS Disorders Product
Table 69. Bluebird Bio Revenue in Gene Therapy for CNS Disorders Business (2019-2024) & (US$ Million)
Table 70. Bluebird Bio Recent Development
Table 71. Research Programs/Design for This Report
Table 72. Key Data Information from Secondary Sources
Table 73. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Gene Therapy for CNS Disorders Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Gene Therapy for CNS Disorders Market Share by Type: 2023 VS 2030
Figure 3. Ex Vivo Features
Figure 4. In Vivo Features
Figure 5. Global Gene Therapy for CNS Disorders Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Gene Therapy for CNS Disorders Market Share by Application: 2023 VS 2030
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Gene Therapy for CNS Disorders Report Years Considered
Figure 11. Global Gene Therapy for CNS Disorders Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Gene Therapy for CNS Disorders Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Gene Therapy for CNS Disorders Market Share by Region: 2023 VS 2030
Figure 14. Global Gene Therapy for CNS Disorders Market Share by Players in 2023
Figure 15. Global Top Gene Therapy for CNS Disorders Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for CNS Disorders as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Gene Therapy for CNS Disorders Revenue in 2023
Figure 17. North America Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Gene Therapy for CNS Disorders Market Share by Country (2019-2030)
Figure 19. United States Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Gene Therapy for CNS Disorders Market Share by Country (2019-2030)
Figure 23. Germany Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Gene Therapy for CNS Disorders Market Share by Region (2019-2030)
Figure 31. China Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Gene Therapy for CNS Disorders Market Share by Country (2019-2030)
Figure 39. Mexico Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Gene Therapy for CNS Disorders Market Share by Country (2019-2030)
Figure 43. Turkey Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Gene Therapy for CNS Disorders Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Gilead (Kite Pharma) Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2019-2024)
Figure 46. Amgen (BioVex) Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2019-2024)
Figure 47. Novartis Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2019-2024)
Figure 48. Roche (Spark Therapeutics) Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2019-2024)
Figure 49. Bluebird Bio Revenue Growth Rate in Gene Therapy for CNS Disorders Business (2019-2024)
Figure 50. Bottom-up and Top-down Approaches for This Report
Figure 51. Data Triangulation
Figure 52. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
